Expression of α ₁ -Adrenoceptor Subtype mRNA as a Predictor of the Efficacy of Subtype Selective α ₁ -Adrenoceptor Antagonists in the Management of Benign Prostatic Hyperplasia

Abstract

The expression level of alpha1-adrenoceptor subtype mRNA in the prostate could be a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in patients with benign prostatic hyperplasia. This result implies that genetic differences are responsible for the diverse responses to these drugs.